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ABSTRACT
Objectives To evaluate the ability of glial fibrillary 
acidic protein (GFAP) and ubiquitin C-terminal hydrolase 
(UCH-L1) to detect concussion in children and adult 
trauma patients with a normal mental status and assess 
biomarker concentrations over time as gradients of injury 
in concussive and non-concussive head and body trauma.
Design Large prospective cohort study.
Setting Three level I trauma centres in the USA.
Participants Paediatric and adult trauma patients of 
all ages, with and without head trauma, presenting with a 
normal mental status (Glasgow Coma Scale score of 15) 
within 4 hours of injury. Rigorous screening for concussive 
symptoms was conducted. Of 3462 trauma patients 
screened, 751 were enrolled and 712 had biomarker data. 
Repeated blood sampling was conducted at 4, 8, 12, 16, 
24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168 
and 180 hours postinjury in adults.
Main outcomes Detection of concussion and gradients 
of injury in children versus adults by comparing three 
groups of patients: (1) those with concussion; (2) those 
with head trauma without overt signs of concussion 
(non-concussive head trauma controls) and (3) those 
with peripheral (body) trauma without head trauma or 
concussion (non-concussive body trauma controls).
Results A total of 1904 samples from 712 trauma 
patients were analysed. Within 4 hours of injury, there 
were incremental increases in levels of both GFAP and 
UCH-L1 from non-concussive body trauma (lowest), 
to mild elevations in non-concussive head trauma, to 
highest levels in patients with concussion. In concussion 
patients, GFAP concentrations were significantly higher 
compared with body trauma controls (p<0.001) and 
with head trauma controls (p<0.001) in both children 
and adults, after controlling for multiple comparisons. 
However, for UCH-L1, there were no significant differences 
between concussion patients and head trauma controls 
(p=0.894) and between body trauma and head trauma 
controls in children. The AUC for initial GFAP levels to 
detect concussion was 0.80 (0.73–0.87) in children and 
0.76 (0.71–0.80) in adults. This differed significantly from 
UCH-L1 with AUCs of 0.62 (0.53–0.72) in children and 0.69 
(0.64–0.74) in adults.
Conclusions In a cohort of trauma patients with normal 
mental status, GFAP outperformed UCH-L1 in detecting 
concussion in both children and adults. Blood levels of 
GFAP and UCH-L1 showed incremental elevations across 
three injury groups: from non-concussive body trauma, 
to non-concussive head trauma, to concussion. However, 
UCH-L1 was expressed at much higher levels than GFAP 
in those with non-concussive trauma, particularly in 
children. Elevations in both biomarkers in patients with 
non-concussive head trauma may be reflective of a 
subconcussive brain injury. This will require further study.
InTRODuCTIOn
Glial fibrillary acidic protein (GFAP) and 
ubiquitin C-terminal hydrolase (UCH-L1) 
have been evaluated in several studies to 
determine the need for CT scan and neuro-
surgical intervention in mild to moderate 
traumatic brain injury patients (mmTBI) in 
adults1–7 and more recently in children with 
mmTBI.8–10 In early 2018, GFAP and UCH-L1 
were Food and Drug Administration-ap-
proved for clinical use in adult patients with 
mmTBI to help determine the need for CT 
scan within 12 hours of injury.11 The approval 
was based on the ability to find lesions on 
CT scan but was not approved to diagnose a 
concussion or a mild TBI. Moreover, it was 
not approved for use in children.
Following trauma, patients often have a 
constellation of injuries and it is important 
that TBI biomarkers indicate brain-spe-
cific injury to be clinically useful. A number 
of articles have described how GFAP and 
UCH-L1 were able to distinguish mmTBI 
patients from orthopaedic controls and 
motor vehicle crash (MVC) controls as well 
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as in those TBI patients with negative CTs.1 3 4 In these 
studies, many trauma control patients were exposed to 
significant trauma including the acceleration–decel-
eration vectors of MVCs and substantial falls and both 
GFAP and UCH-L1 showed a graded response to severity 
of injury from normal controls to trauma controls, to 
mmTBI. Moreover, GFAP has consistently shown very 
good specificity to brain injury in cases of polytrauma.3 12 
GFAP has demonstrated the ability to detect intracranial 
lesions in victims of multiple trauma with mild TBI who 
had substantial extracranial injuries and fractures.3
Importantly, there is a group of individuals with head 
trauma who have been significantly understudied, and in 
whom biomarkers are rarely, if at all, examined. These are 
people who experience head trauma without symptoms 
of concussion. They may be classified as having ‘no injury’ 
or they may represent milder forms of concussion that do 
not elicit the typical signs or symptoms associated with 
concussion and are referred to as subconcussive injuries. 
To date, there is a paucity of studies addressing the effects 
of subconcussive head impacts following head trauma. 
The issue of subconcussive trauma has been a particular 
concern in military personnel13 and in athletes, as repet-
itive subconcussive impacts have the potential for long-
term deleterious effects.14–16 Therefore, studying these 
biomarkers in patients with head trauma without symp-
toms could provide unique insights into how neuronal 
and glial biomarkers behave in subconcussive trauma.17
There are insufficient data on the diagnostic accuracy 
of GFAP and UCH-L1 in children and adults in deter-
mining which trauma patients with normal mental status 
have a concussion and how well they perform over time 
following different degrees of mild head trauma. This 
study evaluated the diagnostic accuracy of serum glial 
and neuronal serum biomarkers GFAP and UCH-L1, 
both individually and in combination, in detecting the 
presence of a concussion and grading potential subcon-
cussive and non-concussive brain injury in paediatric 
and adult trauma patients presenting to the emergency 
department with a normal mental status (Glasgow Coma 
Scale (GCS) score of 15). Gradients of brain injury were 
defined by comparing serum biomarker concentrations 
in three groups of patients: (1) those with concussion, 
(2) those with blunt head trauma without overt signs or 
symptoms of concussion (head trauma controls) and 
(3) those with peripheral (body) trauma without head 
trauma or concussion (body trauma controls). In addi-
tion, the temporal profiles of GFAP and UCH-L1 were 
measured over 7 days in these three groups in adults.
MeThODS
Study population
This prospective cohort study enrolled a convenience 
sample of adult and paediatric trauma patients presenting 
to the emergency departments of three level I trauma 
centres: a paediatric level 1 trauma centre in Philadel-
phia, Pennsylvania; a paediatric level 1 trauma centre in 
Orlando, Florida; and an affiliated adult level 1 trauma 
centre in Orlando, Florida. This study was approved by 
the respective institutional review boards (IRBs) of each 
institution. Informed consent was obtained from patients 
and/or their legal authorised representatives prior to 
enrolment, and assent was obtained for children between 
the ages of 7 and 18 years.
Eligibility for concussion patients was determined by 
the treating physician based on the history of blunt head 
trauma followed by either loss of consciousness, amnesia 
or disorientation (or change in behaviour in children) 
and presenting to the emergency department within 
4 hours of injury with a GCS score of 15. Eligibility was also 
prospectively verified by the research team prior to enrol-
ment. Head CT scans were performed at the discretion 
of the treating physician. Patients were excluded if they: 
(1) had no history of trauma as their primary event (eg, 
syncope or seizure), (2) had known dementia, chronic 
psychosis or active central nervous system pathology, (3) 
were pregnant, (4) were incarcerated or (5) had haemo-
dynamic instability.
Both non-concussive trauma groups, the body trauma 
control patients (no head trauma and no concussion) 
and the head trauma control patients (head trauma and 
no concussion) had a GCS score of 15 presenting to the 
emergency department with a traumatic mechanism of 
injury but without concussion. They experienced similar 
mechanisms of injury as the concussion group and all 
had a normal mental status since injury (as verified by 
the research team prospectively by at least two different 
sources) and had no evidence of acute brain injury or 
haemodynamic instability. Peripheral (body) trauma 
controls were primarily composed of orthopaedic and 
soft tissue injuries. These patients were carefully screened 
to ensure they had no loss of consciousness, no amnesia 
and no alteration in sensorium at any time after injury. 
The purpose of enrolling non-concussive body trauma 
controls and non-concussive head trauma controls was 
to have appropriate comparison groups to compare the 
accuracy of the biomarkers in detecting concussion and 
simulate the real-world challenges faced by clinicians. 
The head trauma controls provided an opportunity to 
assess biomarker release in the setting of head trauma 
without symptoms and the potential for subconcussive 
brain injury.
Study procedures
All initial patient assessments were made by board certi-
fied adult and paediatric emergency medicine physicians 
trained by a formal 1 hour session on evaluating patient 
eligibility for the study. Following the initial screening, a 
meticulous secondary assessment was conducted by the 
research team. All prehospital and emergency depart-
ment records were reviewed; patients, families and 
witnesses (if available) were carefully questioned; and 
the final determination was made by the emergency 
physician together with the research team. Patient clas-
sification was performed prospectively. Blood samples 
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Figure 1 Flow diagram of screened and enrolled patients. 
GCS, Glasgow Coma Scale.
were obtained within 4 hours of time of injury. Repeated 
blood sampling was conducted for as long as the patient 
remained in hospital at 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 
96, 108, 120, 132, 144, 156, 168 and 180 hours after injury 
and discontinued when discharged. Patient manage-
ment was not altered by the study. For each blood draw, a 
single vial of approximately 5 mL of blood was collected 
and placed in a serum separator tube and allowed to clot 
at room temperature. The blood was centrifuged within 
30 min and the serum was placed in bar-coded aliquot 
containers and stored in a freezer at −70°C until it was 
transported to a central laboratory (Banyan Biomarkers, 
Alachua, Florida, USA). There, the samples were analysed 
in batches using sandwich ELISA to GFAP and UCH-L1. 
Laboratory personnel running the samples were blinded 
to the clinical data.
Outcome measures
Performance of GFAP and UCH-L1 was evaluated within 
4 hours of injury in both adults and children and over a 
7-day period in hospitalised adults. The main outcome 
measures included the performance of the biomarkers 
in: (1) detecting the presence of concussion compared 
with trauma patients without concussion in children and 
adults (separately and as a whole); (2) assessing gradients 
of injury defined by comparing three groups of patients: 
(A) those with concussion, (B) those with head trauma 
without overt signs of concussion (non-concussive head 
trauma controls) and (C) those with peripheral (body) 
trauma without head trauma or concussion (non-concus-
sive body trauma controls); and (3) determining the time 
course of GFAP and UCH-L1 over 7 days after injury in 
these three groups in adults.
Statistical analysis
Descriptive statistics with means, medians, and propor-
tions were used to describe the data. For statistical anal-
ysis, biomarker levels were treated as continuous data, 
measured in nanogram per millilitre and expressed as 
medians with IQR. Data were assessed for equality of vari-
ance and distribution. Logarithmic transformations were 
conducted on non-normally distributed data. Group 
comparisons for different trauma groups were performed 
using analysis of variance with multiple comparisons 
using Games-Howell post hoc test. Receiver operating 
characteristics (ROC) curves were created to explore 
the ability of the biomarkers to identify the presence of 
a concussion. Estimates of the area under these curves 
(AUC) were obtained (AUC=0.5 indicates no discrimina-
tion and an AUC=1.0 indicates a perfect diagnostic test).
A power analysis yielded a sample of 281 cases of 
concussion and 141 cases without concussion achieves 
an 80% power to detect a difference of 0.06 between the 
area under the ROC curve under the null hypothesis of 
0.81 and an AUC under the alternative hypothesis of 0.75 
using a two-sided z-test at a significance level of 0.05. All 
analyses were performed using the statistical software 
package SPSS V.22.0 (IBM, Somers, New York, USA).
Biomarker analysis
Serum GFAP and UCH-L1 levels were measured in dupli-
cate for each sample using a validated ELISA platform 
(Banyan Biomarkers, Alachua, Florida, USA). For the 
GFAP assay, the lower limit of quantification (LLOQ) is 
0.030 ng/mL and upper limit of quantification (ULOQ) 
is 50 ng/mL. The limit of detection (LoD) is 0.008 ng/
mL. For the UCH-L1 assay, the LLOQ is 0.100 ng/mL 
and ULOQ is 9 ng/mL. The LoD is 0.045 ng/mL. Any 
samples yielding a signal over the quantification or cali-
brator range were diluted and reassayed.
Patient and public involvement
Patients and the public were not involved in the design, 
recruitment or conduct of the study.
ReSulTS
Over the study period, 3462 paediatric and adult trauma 
patients were screened, 1385 met eligibility criteria, 
751 with a GCS score of 15 were enrolled and 712 had 
biomarker data available for analysis (figure 1). Of those 
enrolled, 371 (52%) had a concussion, 149 (21%) had 
non-concussive head trauma (head trauma controls) 
and 192 (27%) had non-concussive body trauma without 
head trauma (body trauma controls). The flow diagram 
in figure 1 describes the distribution of enrolled patients. 
There were 175 (25%) children and 537 (75%) adults. 
The distribution of clinical characteristics of all enrolled 
patients is presented in table 1. The overall injury severity 
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Figure 2 Temporal profile of GFAP and UCH-L1 in three groups of trauma patients. (A) Temporal profile of GFAP and UCH-L1 
in body trauma control patients. Means with error bars representing SEM. (B) Temporal profile of GFAP and UCH-L1 in head 
trauma control patients. Means with error bars representing SEM. (C) Temporal profile of GFAP and UCH-L1 in trauma patients 
with concussion. Means with error bars representing SEM. GFAP, glialfibrillary acidic protein; UCH-L1, ubiquitinC-terminal 
hydrolase.
score in children and adults was consistent with median 
scores of 4.
There were a total of 1904 samples drawn in 712 patients. 
Patients had serum samples drawn within 4 hours of injury 
(16 children had samples drawn between 4 and 8 hours) 
with the average time from injury to serum sample collec-
tion of 3.1 hours (SD=0.9). Seven hundred and twelve 
patients had initial samples drawn at enrolment, 567 
patients had samples at 4 hours postinjury, 109 at 8 hours 
postinjury, 80 at 12 hours postinjury, 73 at 16 hours post-
injury, 70 at 20 hours postinjury, 67 at 24 hours postin-
jury, 46 at 36 hours postinjury, 40 at 48 hours postinjury, 
33 at 60 hours postinjury, 32 at 72 hours postinjury, 
20 at 84 hours postinjury, 17 at 96 hours postinjury, 8 
at 108 hours postinjury, 8 at 120 hours postinjury, 4 
at 132 hours postinjury, 6 at 144 hours postinjury, 6 at 
156 hours postinjury and 4 at 168 hours postinjury.
Among body trauma control patients, 229 (60%) 
samples were below the LLOD and 90 (24%) below the 
LLOQ for GFAP. In head trauma control patients, 144 
(38%) samples were below the LLOD and 88 (24%) 
below the LLOQ for GFAP. In concussion patients, 
276 (24%) samples were below the LLOD and 172 
(15%) below the LLOQ for GFAP. Among body trauma 
control patients, 61 (16%) samples were below the 
LLOD and 70 (19%) below the LLOQ for UCH-L1. In 
head trauma control patients, 34 (9%) samples were 
below the LLOD and 39 (10%) below the LLOQ for 
UCH-L1. In concussion patients, 128 (11%) samples 
were below the LLOD and 103 (11%) below the LLOQ 
for UCH-L1.
The time course of GFAP and UCH-L1 over a week post-
trauma is depicted in figure 2 and contrasted in three 
groups of patients (concussion, head trauma controls 
and body trauma controls). In the concussion patients, 
the serum concentration of GFAP was detectable within 
1 hour of injury and reached a peak at 20 hours post-
injury and decreased over 72 hours. GFAP concentra-
tions exhibited a slower decline thereafter but were still 
detectable at 168 hours (7 days) postinjury. In contrast, 
UCH-L1 rose very rapidly after injury, reached a peak at 
8 hours, decreased quickly to 12 hours and was followed 
by a slower decline to 60 hours postinjury. Subsequently, 
UCH-L1, like GFAP, exhibited some smaller peaks and 
toughs over 7 days and was also detectable at 168 hours 
postinjury.
In head trauma controls, GFAP levels were remarkably 
lower than in the concussion patients with very slight 
elevations until 48 hours. The peak appeared at 20 hours 
(as in the concussion patients) and after 48 hours, GFAP 
levels remained almost undetectable. Interestingly, in 
head trauma controls UCH-L1 levels peaked within 
4 hours and remained lower than concussion patients 
over 12 hours. Thereafter, UCH-L1 concentrations 
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Table 2 Area under the curve for distinguishing between concussion and body trauma controls (no head trauma and no 
concussion symptoms)
Hours postinjury GFAP UCH-L1
Combination of GFAP and 
UCH-L1
Enrolment (children) (n=141) 0.80 (0.73–0.87) 0.62 (0.53–0.72) 0.80 (0.73–0.87)
Enrolment (adults) (n=422) 0.76 (0.71–0.80) 0.69 (0.64–0.74) 0.78 (0.73–0.82)
Enrolment (both) (n=563) 0.76 (0.72–0.80) 0.67 (0.63–0.72) 0.78 (0.74–0.81)
4 hours (n=452) 0.76 (0.72–0.80) 0.65 (0.60–0.70) 0.77 (0.73–0.81)
8 hours (n=92) 0.82 (0.72–0.91) 0.72 (0.56–0.87) 0.86 (0.75–0.96)
12 hours (n=68) 0.83 (0.73–0.93) 0.74 (0.58–0.90) 0.85 (0.74–0.96)
16 hours (n=66) 0.84 (0.73–0.95) 0.77 (0.62–0.91) 0.86 (0.75–0.97)
20 hours (n=61) 0.82 (0.71–0.94) 0.63 (0.43–0.84) 0.82 (0.70–0.94)
24 hours (n=56) 0.87 (0.76–0.98) 0.74 (0.58–0.90) 0.87 (0.74–1.00)
36 hours (n=35) 0.86 (0.72–1.00) 0.76 (0.51–1.00) 0.90 (0.76–1.00)
48 hours (n=30) 0.85 (0.68–1.00) 0.71 (0.53–0.90) 0.85 (0.65–1.00)
60 hours (n=27) 0.79 (0.57–1.00) 0.70 (0.50–0.90) 0.83 (0.61–1.00)
72 hours (n=25) 0.87 (0.71–1.00) 0.78 (0.56–1.00) 0.94 (0.82–1.00)
84 hours (n=15) 0.89 (0.69–1.00) 0.75 (0.40–1.00) 0.89 (0.69–1.00)
96 hours (n=13) 0.75 (0.39–1.00) 0.54 (0.18–0.90) 0.75 (0.49–1.00)
108 hours (n=6) n/a n/a n/a
120 hours (n=6) 0.80 (0.40–1.00) 0.50 (0.05–0.23) 0.90 (0.62–1.00)
132 hours (n=2) n/a n/a n/a
144 hours (n=4) n/a n/a n/a
156 hours (n=4) n/a n/a n/a
168 hours (n=2) n/a n/a n/a
In this table, performance of GFAP and UCH-L1 alone and in combination is shown.
GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase; n/a, data not available.
become quite variable with levels either slightly lower, at 
par or slightly higher than concussion patients.
In body trauma control patients, concentrations of 
GFAP were negligible over time without any appreciable 
elevations. Initial UCH-L1 levels were slightly elevated 
but significantly lower than either head trauma or 
concussion patients. UCH-L1 levels decreased quickly 
over 12 hours (as it did in the head trauma controls) and 
levels remained noticeably elevated over the next several 
days.
The ability of GFAP and UCH-L1, individually and in 
combination, to distinguish concussion patients from 
body trauma controls (table 2) and head trauma controls 
(table 3) over time was assessed by calculating the area 
under the ROC curve at each timepoint postinjury. A 
comparison between concussion and both trauma and 
head trauma controls can be found in table 4. When 
comparing concussion patients to body trauma controls, 
GFAP demonstrated a range of AUCs between 0.75 
(0.39–1.00) and 0.89 (0.69–1.00) and UCH-L1 demon-
strated AUCs between 0.50 (0.05–0.23) and 0.78 (0.56–
1.00). When GFAP and UCH-L1 were combined, the 
AUC ranged from 0.75 (0.49–1.00) to 0.90 (0.76–1.00) 
and closely mimicked the pattern of GFAP. GFAP outper-
formed UCH-L1 at all timepoints. The combination of 
GFAP and UCH-L1 marginally outperformed GFAP 
alone at some timepoints; however, the differences were 
not statistically significant.
When comparing concussion patients to head trauma 
controls, GFAP demonstrated a range of AUCs between 
0.62 (0.57–0.68) and 0.86 (0.73–1.00) and UCH-L1 
demonstrated AUCs between 0.13 (0–1.00) and 0.61 
(0.49–0.73). When GFAP and UCH-L1 were combined, 
the AUC ranged from 0.33 (0–0.71) to 0.86 (0.73–1.00). 
GFAP outperformed UCH-L1 at all timepoints and 
outperformed the combination of the two biomarkers at 
all timepoints.
A comparison of the performance of GFAP and 
UCH-L1 measured within 4 hours of injury in children 
and adults is shown in figure 3. There are incremental 
increases in levels of GFAP and UCH-L1 from non-con-
cussive body trauma controls to non-concussive head 
trauma controls to patients with concussion. In concus-
sion patients, GFAP concentrations were significantly 
higher compared with body trauma controls (p<0.001) 
and to head trauma controls (p<0.001) in both chil-
dren and adults, after controlling for multiple compari-
sons. There were also significantly higher levels of GFAP 
in head trauma controls compared with body trauma 
controls in children (p<0.001) and adults (p<0.001). 
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Table 3 Area under the curve for distinguishing between concussion and head trauma controls (no concussion symptoms) in 
patients with head trauma
Hours postinjury GFAP UCH-L1
Combination of GFAP and 
UCH-L1
Enrolment (children) (n=128) 0.64 (0.54–0.73) 0.54 (0.43–0.66) 0.63 (0.53–0.72)
Enrolment (adults) (n=392) 0.66 (0.61–0.71) 0.58 (0.51–0.64) 0.66 (0.61–0.72)
Enrolment (both) (n=520) 0.65 (0.60–0.70) 0.56 (0.51–0.62) 0.65 (0.60–0.70)
4 hours (n=421) 0.62 (0.57–0.68) 0.55 (0.49–0.61) 0.62 (0.57–0.88)
8 hours (n=99) 0.72 (0.61–0.82) 0.61 (0.49–0.73) 0.72 (0.61–0.82)
12 hours (n=74) 0.69 (0.55–0.82) 0.51 (0.37–0.66) 0.67 (0.54–0.80)
16 hours (n=69) 0.76 (0.64–0.88) 0.58 (0.39–0.76) 0.74 (0.62–0.85)
20 hours (n=65) 0.68 (0.53–0.83) 0.41 (0.23–0.59) 0.66 (0.52–0.81)
24 hours (n=64) 0.74 (0.60–0.88) 0.40 (0.24–0.56) 0.72 (0.59–0.86)
36 hours (n=44) 0.76 (0.61–0.91) 0.56 (0.37–0.75) 0.76 (0.61–0.92)
48 hours (n=38) 0.81 (0.67–0.95) 0.52 (0.32–0.73) 0.79 (0.64–0.93)
60 hours (n=31) 0.86 (0.73–1.00) 0.54 (0.34–0.74) 0.86 (0.73–1.00)
72 hours (n=30) 0.78 (0.60–0.95) 0.43 (0.20–0.66) 0.71 (0.51–0.91)
84 hours (n=19) 0.84 (0.65–1.00) 0.37 (0.13–0.62) 0.74 (0.52–0.97)
96 hours (n=16) 0.75 (0.51–0.99) 0.28 (0.02–0.55) 0.65 (0.38–0.91)
108 hours (n=8) 0.67 (0.26–1.00) 0.17 (0–0.47) 0.33 (0–0.71)
120 hours (n=7) 0.80 (0.46–1.00) 0.20 (0–0.58) 0.70 (0.30–1.00)
132 hours (n=4) 0.75 (0.20–1.00) 0 (0–0) 0.50 (0–1.00)
144 hours (n=6) 0.75 (0.20–1.00) 0 (0–0) 0.50 (0.01–0.99)
156 hours (n=6) 0.75 (0.34–1.00) 0 (0–0) 0.50 (0.01–0.99)
168 hours (n=4) 0.75 (0.20–1.00) 0.13 (0–1.00) 0.63 (0–1.00)
In this table, performance of GFAP and UCH-L1 alone and in combination is shown.
GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase.
In adults, concentrations of UCH-L1 measured within 
4 hours of injury were also significantly higher in concus-
sion patients than body trauma controls (p<0.001) 
and head trauma controls (p=0.002). There were also 
significantly higher levels of UCH-L1 in head trauma 
controls compared with body trauma controls (p=0.017). 
Similarly, in children, concentrations of UCH-L1 were 
significantly higher in concussion patients than that in 
body trauma controls (p=0.045). However, there were 
no significant differences between concussion patients 
and head trauma controls (p=0.894) and between body 
trauma and head trauma controls in children.
When ROC curves were compared in children and 
adults, the AUCs demonstrated that initial GFAP levels 
were able to distinguish concussion patients from body 
trauma controls with an AUC of 0.80 (0.73–0.87) in chil-
dren and 0.76 (0.71–0.80) in adults (table 2). In contrast, 
initial UCH-L1 levels distinguished concussion from body 
trauma controls with a significantly lower AUC of 0.62 
(0.53–0.72) in children (p=0.003) and 0.69 (0.64–0.74) in 
adults (p=0.04) (table 2). The AUCs for GFAP for distin-
guishing concussion patients from head trauma controls 
were 0.64 (0.54–0.73) in children and 0.66 (0.61–0.71) in 
adults. AUCs were lower for UCH-L1 with an AUC of 0.54 
(0.43–0.66) in children (p=0.23) and 0.58 (0.51–0.64) in 
adults (p=0.04) (table 3). Overall, when concussion was 
compared with all (head and body) trauma control cases 
without concussion, the AUC for GFAP was 0.73 (0.66–
0.81) in children and 0.71 (0.67–0.76) in adults. AUCs 
were significantly lower for UCH-L1 with an AUC of 0.59 
(0.51–0.67) in children (p=0.013) and 0.64 (0.59–0.69) 
in adults (p=0.030) (table 4). There were significantly 
higher levels of GFAP and UCH-L1 in those with intra-
cranial lesions on CT; therefore, we excluded the 36 
(8%) patients with CT lesions and found similar results 
(figure 4).
DISCuSSIOn
This prospective study assessed the diagnostic accuracy 
of glial and neuronal biomarkers, GFAP and UCH-L1, 
for detecting concussion in a very large cohort of chil-
dren and adult trauma patients presenting to three level 
I trauma centres. The study investigated the pattern of 
biomarker release in trauma patients with and without 
concussion at 20 distinct timepoints, making it among the 
first and largest studies to assess the temporal profile of 
these two biomarkers in three groups of trauma patients 
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Table 4 Area under the curve for distinguishing between concussion and all trauma controls (head and body controls with no 
concussion)
Hours postinjury trauma GFAP UCH-L1
Combination of GFAP and 
UCH-L1
Enrolment (children) (n=175) 0.73 (0.66–0.81) 0.59 (0.51–0.67) 0.73 (0.65–0.80)
Enrolment (adults) (n=537) 0.71 (0.67–0.76) 0.64 (0.59–0.69) 0.73 (0.68–0.77)
Enrolment (both) (n=712) 0.71 (0.67–0.75) 0.63 (0.59–0.67) 0.72 (0.68–0.76)
4 hours (n=567) 0.70 (0.66–0.74) 0.61 (0.56–0.65) 0.70 (0.66–0.75)
8 hours (n=109) 0.75 (0.66–0.84) 0.65 (0.54–0.75) 0.77 (0.68–0.86)
12 hours (n=80) 0.73 (0.62–0.85) 0.59 (0.46–0.72) 0.73 (0.62–0.85)
16 hours (n=73) 0.79 (0.69–0.90) 0.64 (0.49–0.80) 0.78 (0.68–0.89)
20 hours (n=70) 0.73 (0.61–0.86) 0.49 (0.33–0.65) 0.72 (0.59–0.84)
24 hours (n=67) 0.77 (0.64–0.89) 0.47 (0.31–0.63) 0.75 (0.63–0.88)
36 hours (n=46) 0.77 (0.63–0.91) 0.59 (0.41–0.77) 0.78 (0.64–0.92)
48 hours (n=40) 0.81 (0.68–0.95) 0.55 (0.37–0.74) 0.80 (0.66–0.93)
60 hours (n=33) 0.85 (0.71–0.98) 0.58 (0.39–0.77) 0.86 (0.73–0.98)
72 hours (n=32) 0.80 (0.64–0.95) 0.51 (0.29–0.73) 0.76 (0.59–0.94)
84 hours (n=20) 0.85 (0.67–1.00) 0.44 (0.18–0.69) 0.77 (0.56–0.98)
96 hours (n=17) 0.75 (0.51–0.98) 0.33 (0.07–0.60) 0.67 (0.41–0.92)
108 hours (n=8) 0.67 (0.26–1.00) 0.17 (0–0.47) 0.33 (0–0.71)
120 hours (n=8) 0.80 (0.48–1.00) 0.30 (0–0.69) 0.77 (0.42–1.00)
132 hours (n=4) 0.75 (0.20–1.00) 0 (0–0) 0.50 (0–1.00)
144 hours (n=6) 0.75 (0.34–1.00) 0 (0–0) 0.50 (0.01–0.99)
156 hours (n=6) 0.75 (0.34–1.00) 0.38 (0–0.85) 0.63 (0.15–1.00)
168 hours (n=4) 0.75 (0.20–1.00) 0.13 (0–1.00) 0.63 (0–1.00)
In this table, performance of GFAP and UCH-L1 alone and in combination is shown.
GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin C-terminal hydrolase.
with a normal mental status. In both children and adults, 
GFAP and UCH-L1 concentrations increased incre-
mentally from those with non-concussive body trauma 
to those with non-concussive head trauma with highest 
levels in patients with concussion. GFAP showed very 
distinct patterns of release in all three groups, whereas 
UCH-L1 demonstrated similar patterns of release in 
all three groups but at much higher concentrations in 
both non-concussive trauma groups. There were signif-
icant differences between the three groups controlling 
for multiple comparisons for both biomarkers in adults; 
however, UCH-L1 could not distinguish concussive from 
non-concussive head trauma in children.
When the time course of GFAP and UCH-L1 was 
contrasted in three groups of patients (concussion, 
head trauma controls and body trauma controls), GFAP 
showed a clear increase over the first 20 hours postinjury 
and decline from 20 to 72 hours in concussion patients 
and was still detectable at 7 days postinjury making it 
potentially useful over a week from injury. Although 
GFAP was mildly elevated in head trauma without 
concussion, the expression was very low and very early 
compared with concussion. In body trauma control 
patients, concentrations of GFAP were negligible over all 
timepoints suggesting very good specificity for concus-
sion. These results are consistent with previous studies 
showing how robust it is in multiple trauma.3 4 In contrast, 
UCH-L1 rose more rapidly after concussion than GFAP, 
peaking within 8 hours and steadily decreasing from 12 to 
60 hours. Unexpectedly, UCH-L1 was much higher in the 
head trauma control group compared with GFAP at all 
timepoints from injury over 7 days. Even more surprising, 
was that UCH-L1 was elevated in body trauma too and 
showed a similar pattern of release as head trauma 
control patients. Possible explanations for UCH-L1 eleva-
tions in control patients include that (1) UCH-L1 may not 
be completely brain specific and is released from other 
organ or tissue trauma or (2) UCH-L1 is an ultrasensitive 
marker of any neuronal disruption that may occur from 
impacts to the body that jostle the brain.
Given that GFAP appears to be so brain specific and 
that it also showed low level elevations in the first 48 hours 
following head trauma without concussion symptoms 
(head trauma controls), these elevations may represent 
milder forms of concussion that do not elicit typical signs 
or symptoms associated with concussion. These inju-
ries may be irrelevant, or they may represent important 
trauma that is just below the level of clinical detection and 
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Figure 3 Boxplot comparing initial levels of GFAP and UCH-L1 in three groups of trauma patients: (1) trauma controls without 
head trauma (controls), (2) head trauma controls without concussion (no concussion) and (3) head trauma with concussion 
(concussion). There were 47, 34 and 94 children in each group, respectively, and 145, 115 and 277 adult patients, respectively. 
Medians with bars representing IQR. GFAP, glialfibrillary acidic protein; UCH-L1, ubiquitinC-terminal hydrolase.
referred to as subconcussive trauma. Emerging data have 
demonstrated that significant alterations in brain func-
tion can occur in the absence of clinically obvious symp-
toms following even a single head trauma.15 18 19 Given 
the lack of concussive symptoms acutely, biomarkers 
(such as GFAP and UCH-L1) could provide a more objec-
tive measure of injury and potentially identify those at 
risk for neurocognitive problems. Studies in athletes have 
documented that both clinically diagnosed concussion 
and subconcussive traumas can induce similar changes 
in brain structure and functions on brain imaging.15 19–21 
These changes include alterations in white matter and 
cerebrovascular integrity, blood flow, neuroinflamma-
tion, brain activation during working memory tasks, rest-
ing-state functional connectivity and brain chemistry as 
measured by various forms of MRI.20 22 23 The effect of 
thousands of subconcussive impacts has the potential 
for long-term deleterious effects on brain function and 
neurodegeneration in select individuals.14 15 19 In athletes, 
UCH-L1 has shown elevations in both concussive24 and 
subconcussive trauma.25
To date, there is a lack of research addressing the effects 
of subconcussive head impacts following head trauma in 
an emergency department population. Acute biomarkers 
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Figure 4 ROC curves comparing initial levels of GFAP and UCH-L1 (individually and in combination) for predicting a 
concussion in trauma patients excluding patients with traumatic intracranial lesions on CT. GFAP, glialfibrillary acidic protein; 
ROC, receiver operating characteristics; UCH-L1, ubiquitinC-terminal hydrolase.
may have a role in assessing these patients if the markers 
can be shown to correlate with long-term neurocogni-
tive dysfunction. Most recently, microRNA biomarkers 
measured pre-season and post-season in collegiate foot-
ball players were associated with worsening neurocogni-
tive functioning over the course of a season in those with 
no concussions.26
Concussion is a clinical diagnosis that could benefit 
from a relatively non-invasive complementary tool such 
as a blood test.8 9 27–29 Based on these results, the poten-
tial utility of GFAP to distinguish concussion from body 
trauma controls over 7 days postinjury was fair to excel-
lent with AUCs of 0.75 to 0.89, and UCH-L1’s ability 
was guarded and variable with AUCs from poor to good 
depending on timing of samples (AUCs of 0.54 to 0.78) 
with earlier samples being better. The combination of the 
both biomarkers did not significantly improve concus-
sion detection among trauma control patients. The 
distinction between patients with head trauma with and 
without concussion was not as robust as with body trauma 
controls. GFAP performed with fair to very good AUCs 
(0.62 to 0.86) over the week postinjury, with optimal 
performance between 24 and 96 hours. The ability of 
UCH-L1 to distinguish concussion from head trauma 
control patients was very poor with AUCs of 0.13–0.61 
and did not contribute to or improve the performance 
of GFAP alone.
Since it is not uncommon for patients who have suffered 
a concussion or mild TBI not to seek immediate medical 
attention, understanding when to use the biomarkers 
for detection of injury is critical. In the context of devel-
oping a point-of-care test, UCH-L1’s early and rapid rise 
could be useful in the early postinjury setting such as in 
the ambulance, on the playing field or on the battlefield. 
The longer half-life of GFAP makes it a very favourable 
marker to use in both the acute and subacute phases of 
injury as it can detect concussion for up to 7 days after 
injury.
The authors recognise that there are limitations to this 
study. This study addressed diagnosis of concussion in the 
acute care setting and did not describe long-term outcome 
in these patients. The main outcomes used in this study 
reflect current standards of practice and accepted defi-
nitions of concussion. However, future studies to better 
define the severity of concussion and mild TBI need to 
be pursued, particularly when neuroimaging is negative. 
Accordingly, we performed an analysis of patients with 
negative neuroimaging acutely and found no significant 
differences in the results whether we included those with 
positive scans or not. The number of samples available 
for analysis decreased over the course of the study. This 
reflects the challenge of obtaining samples over time in 
patients with less severe injuries because they are not 
hospitalised as long. However, there were many patients 
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without TBI and patients with mild TBI who were 
captured in our longitudinal sample because they were 
admitted for other injuries. Important next steps will be 
to capture samples within minutes of injury. Uninjured 
controls were not included in this analysis as the concen-
trations of these two biomarkers have already been well 
characterised in uninjured normal control patients.1 2
COnCluSIOnS
In a cohort of trauma patients with normal mental status, 
GFAP outperformed UCH-L1 in detecting concussion 
in both children and adults. Blood levels of GFAP and 
UCH-L1 showed incremental elevations across three 
injury groups: from non-concussive body trauma, to 
non-concussive head trauma, to concussion. However, 
UCH-L1 was expressed at much higher levels than GFAP 
in those with non-concussive trauma, particularly in chil-
dren, suggesting that UCH-L1 is either not completely 
brain specific or ultrasensitive to subtle impacts. Each 
biomarker exhibited a distinct temporal profile in each 
trauma group over 7 days with earlier elevations in 
UCH-L1 and more consistent and sustained elevations 
in GFAP. Furthermore, elevations in both biomarkers in 
patients with non-concussive head trauma may be reflec-
tive of a subconcussive brain injury. The stage is set for 
future studies to verify these findings.
What is known about the subject?
 ► In 2018, serum biomarkers GFAP and UCH-L1 were Food and Drug 
Administration-approved in adults to guide CT scan ordering in mild 
to moderate traumatic brain injury. However, their ability to detect 
concussion in either children or adults has not been determined and 
there currently exists no objective measure to diagnose concussion 
acutely after injury. The challenge for clinicians is to detect concus-
sion in the setting of head and/or peripheral trauma when patients 
have a normal mental status.
What this study adds?
 ► GFAP outperformed UCH-L1 in detecting concussion in both chil-
dren and adults within 4 hours of injury. Blood levels of GFAP and 
UCH-L1 showed incremental elevations across three injury groups: 
from non-concussive body trauma, to non-concussive head trauma, 
to concussion. UCH-L1 was expressed at much higher levels than 
GFAP in those with non-concussive trauma, particularly in children. 
Elevations of these biomarkers in non-concussive head trauma 
suggests possible subconcussive brain injury. GFAP could be po-
tentially useful to detect concussion for up to a week postinjury.
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